Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Cytarabine 9fludarabine phosphate 8fludarabine 8Radiotherapy 7Vincristine 5Cyclosporine 5Whole-Body Irradiation 4Prednisone 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Etoposide 4Busulfan 4asparaginase erwinia chrysanthemi recombinant 3Tacrolimus 3Sirolimus 3Dasatinib 3Cord Blood Stem Cell Transplantation 3Bortezomib 3Asparaginase 3prednylidene 2pegaspargase 2ixazomib 2deltacortene 2blinatumomab 2Thiotepa 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Precursor Cell Lymphoblastic Leukemia-Lymphoma × duvelisib × Clear all
NCT02028039 2014-01-06

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡